The role of COX-2 in intestinal cancer

Bibliography

• Figures 1995, CFa. American Cancer Society (1995).
   Google Scholar
• MIYAMOTO T, OGINO N, YAMAMOTO S, HAYAISHI 0: Purification of prostaglandin endoperoxide syn-thetase from bovine vesicular gland microsomes. J. Biol. Chem. (1976) 251:2629–2636.
   PubMed Web of Science ®Google Scholar
• MILLER TA: Protective effects of prostaglandins against gastric mucosal damage: current knowledge and pro-posed mechanisms. Am. J. Physic)]. (1983) 245:G601–623.
   PubMed Web of Science ®Google Scholar
• SIMMONS DL, LEVY DB, YANNONI Y, ERIKSON RL: Iden-tification of a phorbol ester-repressible v-src-induc-ible gene. Proc. Natl. Acad. ScL USA (1989) 86:1178–1182.
   PubMed Web of Science ®Google Scholar
• KUJUBU DA, FLETCHER BS, VARNUM BC, LIM RW,HERSCHMAN HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, en-codes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. (1991) 266:12866–12872.
   PubMed Web of Science ®Google Scholar
• FU JY, MASFERRER JL, SEIBERT K, RAZ A, NEEDLEMAN P:The induction and suppression of prostaglandin 112 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. (1990)265:16737–16740.
   PubMed Web of Science ®Google Scholar
• O'SULLIVAN MG, CHILTON FH, HUGGINS EM, MCCALLCE: Lipopolysaccharide priming of alveolar macro-phages for enhanced synthesis of prostanoids in-volves induction of a novel prostaglandin 11 synthase. J. Biol. Chem. (1992) 267:14547–14550.
   PubMed Web of Science ®Google Scholar
• LEE SH, SOYOOLA E, CHANMUGAM P et al.: Selective ex-pression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem. (1992) 267:25934–25938.
   PubMed Web of Science ®Google Scholar
• KUJUBU DA, HERSCHMAN HR: Dexamethasone inhibitsmitogen induction of the TI510 prostaglandin syn-thase/cyclooxygenase gene. J. Biol. Chem. (1992) 267:7991–7994.
   PubMed Web of Science ®Google Scholar
• COYNE DW, NICKOLS M, BERTRAND W, MORRISON AR:Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids. Am. J. Physiol. (1992) 263:F97–102.
   PubMed Web of Science ®Google Scholar
• JONES DA, CARLTON DP, MCINTYRE TM, ZIMMERMANGA, PRESCOTT SM: Molecular cloning of human prosta-glandin endoperoxide synthase type II and demon-stration of expression in response to cytokines. J. Biol. Chem. (1993) 268:9049–9054.
   PubMed Web of Science ®Google Scholar
• GENG Y, BLANCO F, CORNELISSON M, LOTZ M: Regula-tion of cyclooxygenase-2 expression in normal hu-man articular chondrocytes. J. Immun. (1995) 155:796–801.
   PubMed Web of Science ®Google Scholar
• RYSECK RP, RAYNOSCHEK C, MACDONALD-BRAVO H etal: Identification of an immediate early gene, pghs-B, whose protein product has prostaglandin syn-thase/cyclooxygenase activity. Cell Growth Diff (1992) 3:443–450.
   PubMedGoogle Scholar
• DEWITT DL, MEADE EA: Serum and glucocorticoid regu-lation of gene transcription and expression of prosta-glandin 11 synthase-1 and prostaglandin 11 synthase-2 isozymes. Arch. Biochem. Biophys. (1993) 306:94–102.
   PubMed Web of Science ®Google Scholar
• HAMASAKI Y, KITZLER J, HARDMAN R, NETTESHEIM P,ELING TE: Phorbol ester and epidermal growth factor enhance the expression of two inducible prostaglan-din 11 synthase genes in rat tracheal epithelial cells. Arch. Biochem. Biophys. (1993) 304:226–234.
   PubMed Web of Science ®Google Scholar
• DUBOIS RN, AWAD J, MORROW J, ROBERTS LJ, BISHOPPR: Regulation of eicosanoid production and mito-genesis in rat intestinal epithelial cells by transform-ing growth factor-a and phorbol ester. J. Clin. Invest. (1994) 93:493–498.
   PubMed Web of Science ®Google Scholar
• RIESE J, HOFF T, NORDHOFF A et al.: Transient expres-sion of prostaglandin endoperoxide synthase-2 dur-ing mouse macrophage activation. J. Leuko. Biol. (1994) 55:476–482.
   PubMed Web of Science ®Google Scholar
• BAZAN NG, FLETCHER BS, HERSCHMAN HR, MUKHERJEEPK: Platelet-activating factor and retinoic acid syner-gistically activate the inducible prostaglandin syn-thase gene. Proc. Natl. Acad. Sci. USA (1994) 91:5252–5256.
   PubMed Web of Science ®Google Scholar
• KESTER M, CORONEOS E, THOMAS PJ, DUNN MJ: Endo-thelin stimulates prostaglandin endoperoxide synthase-2 mRNA expression and protein synthesis through a tyrosine kinase-signaling pathway in rat mesangial cells. J. Biol. Chem. (1994) 269:22574–22580.
   PubMed Web of Science ®Google Scholar
• VANE JR: Inhibition of prostaglandin synthesis as amechanism of action for aspirin-like drugs. Nature (1971) 231:232–235.
   Web of Science ®Google Scholar
• FLOWER RJ, VANE JR: Inhibition of prostaglandin syn-thetase in brain explains the anti- pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 240:410–411.
   PubMed Web of Science ®Google Scholar
• Non-steroidal anti-inflammatory drugs: cyclooxyge-nase inhibitors. Drug & Market Development (1997) 8:8–15.
   Google Scholar
• PENNISI E: Building a better aspirin [news; comment].Science (1998) 280:1191–1192.
   PubMed Web of Science ®Google Scholar
• WENNOGLE LP, HANG H, QUINTAVALLA JC et al.: Com-parison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. FEBS Lett. (1995) 371:315–320.
   PubMed Web of Science ®Google Scholar
• XIAO G, TSAI AL, PALMER G et al.: Analysis ofhydroperoxide-induced tyrosyl radicals and lipoxyge-nase activity in aspirin-treated human prostaglandin 11 synthase-2. Biochemistry (1997) 36: 1836-1845.
   Google Scholar
• LANEUVILLE 0, BREUER DK, DEWITT DL et al.: Differen-tial inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol Exp. Ther. (1994) 271:927–934.
   Google Scholar
• COPELAND RA, WILLIAMS JM, GIANNARAS J et al: Mecha-nism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. USA (1994) 91:11202–11206.
   PubMed Web of Science ®Google Scholar
• RIENDEAU D, PERCIVAL MD, BOYCE S et al.: Biochemical and pharmacological profile of a tetrasubstituted fu-ranone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. (1997) 121:105–117.
   PubMed Web of Science ®Google Scholar
• ••This paper along with the paper by Penning et al. exempli-fies the characterisation of pharmacological inhibitors. For non-chemists this paper may seems complex; however, it demonstrates the caveats that must be taken into considera-tion when reporting IC50 values. In addition, they utilise multiple assays for COX activity so that one can compare the values obtained with these different assays.
   Google Scholar
• HIAL V, HORAKOVA Z, SHAFF FE, BEAVEN MA: Altera-tion of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur. Pharmacol (1976) 37:367–376.
   PubMed Web of Science ®Google Scholar
• POLLARD M, LUCKERT PH: Indomethacin treatment ofrats with dimethylhydrazine-induced intestinal tu-mors. Cancer Treat. Rep. (1980) 64:1323-1327. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(1)
   Google Scholar
• POLLARD M, LUCKERT PH: Effect of indomethacin onintestinal tumors induced in rats by the acetate deriva-tive of dimethylnitrosamine. Science (1981) 214:558–559.
   PubMed Web of Science ®Google Scholar
• WADDELL WR, LOUGHRY RW: Sulindac for polyposis ofthe colon. J. Surg. Oncol. (1983) 24:83–87.
   PubMed Web of Science ®Google Scholar
• PELEG II, LUBIN MF, COTSONIS GA, CLARK WS, WILCOXCM: Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subse-quent colorectal neoplasia. Dig. Dis. ScL (1996) 41:1319–1326.
   PubMed Web of Science ®Google Scholar
• GIOVANNUCCI E, RIMM EB, STAMPFER MJ et al: Aspirinuse and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. (1994) 121:241–246.
   PubMed Web of Science ®Google Scholar
• GIOVANNUCCI E, EGAN KM, HUNTER, DJ et al: Aspirinand the risk of colorectal cancer in women. NewEngl. J. Med. (1995) 333:609–614.
   PubMed Web of Science ®Google Scholar
• GANN PH, MANSON JE, GLYNN RJ, BURING JE, HENNE-KENS CH: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl. Cancer Inst. (1993) 85:1220–1224.
   PubMed Web of Science ®Google Scholar
• LABAYLE D, FISCHER D, VIELH P et al: Sulindac causesregression of rectal polyps in familial adenomatous polyposis. Gastroenterology (1991) 101:635–639.
   PubMed Web of Science ®Google Scholar
• GIARDIELLO FM, HAMILTON SR, KRUSH AJ et al.: Treat-ment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl. J. Med. (1993) 328:1313–1316.
   PubMed Web of Science ®Google Scholar
• PASRICHA PJ, BEDI A, O'CONNOR K et al.: The effects ofsulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis [see comments]. Gas-troenterology (1995) 109:994–998.
   Google Scholar
• NUGENT KP, FARMER KC, SPIGELMAN AD, WILLIAMS CB,PHILLIPS RK: Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. (1993) 80:1618–1619.
   PubMed Web of Science ®Google Scholar
• GIARDIELLO FM, SPANNHAKE EW, DUBOIS RN et al:Prostaglandin levels in human colorectal mucosa: ef-fects of sulindac in patients with familial adenomatous polyposis. Dig. Dis. Sci. (1998) 43:311–316.
   PubMed Web of Science ®Google Scholar
• RIGAS B, GOLDMAN IS, LEVINE L: Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. (1993) 122:518–523.
   PubMed Web of Science ®Google Scholar
• ••While it is important to demonstrate that COX-2 is increasedin tumour samples by Western or Northern analysis, it is equally important to demonstrate that prostaglandin levels in these tissue are altered as well. Rigas et al. have demon-strated in 13 out of 22 pairs of surgically excised human co-lon cancer and histologically normal mucosa samples that PGE2 is elevated.
   Google Scholar
• BENNETT A, CIVIER A, HENSBY CN, MELHUISH PB, STAM- FORD IF: Measurement of arachidonate and its metabo-lites extracted from human normal and malignant gastrointestinal tissues. Gut (1987) 28:315–318.
   PubMed Web of Science ®Google Scholar
• EBERHART CE, COFFEY RJ, RADHIKA A et al.: Up-regulation of cyclooxygenase 2 gene expression in hu-man colorectal adenomas and adenocarcinomas. Gas-troenterology (1994) 107:1183–1188.
   PubMed Web of Science ®Google Scholar
• SANO H, KAWAHITO Y, WILDER RL et al.: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. (1995) 55:3785–3789.
   PubMed Web of Science ®Google Scholar
• KUTCHERA W, JONES DA, MATSUNAMI N et al.: Prosta-glandin H synthase-2 is expressed abnormally in hu-man colon cancer: evidence for a transcriptional effect. Proc. Nati Acad. ScL USA (1996) 93:4816–4820.
   PubMed Web of Science ®Google Scholar
• KARGMAN S, O'NEILL G, VICKERS P et al.: Expression ofprostaglandin G/H synthase-1 and -2 protein in hu-man colon cancer. Cancer Res. (1995) 55:2556–2559.
   Google Scholar
• SULK, KINZLER KW, VOGELSTEIN B etal.: Multiple intes-tinal neoplasia caused by a mutation in the murine ho-molog of the APC gene. Science (1992) 256:668–670.
   Google Scholar
• SINGH J, HAMID R, REDDY BS: Dietary fat and colon can-cer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res. (1997) 57:3465–3470.
   PubMed Web of Science ®Google Scholar
• WILLIAMS CS, LUONGO C, RADHIKA A et al: Elevatedcyclooxygenase-2 levels in Min mouse adenomas. Gas-troenterology (1996) 111:1134–1140.
   PubMed Web of Science ®Google Scholar
• DUBOIS RN, RADHIKA A, REDDY BS, ENTINGH AJ: In-creased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology (1996) 110:1259–1262.
   PubMed Web of Science ®Google Scholar
• OSHIMA M, DINCHUK JE, KARGMAN SL et al: Suppres-sion of intestinal polyposis in APCA716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell (1996) 87:803–809.
   PubMed Web of Science ®Google Scholar
• ••Genetic evidence is often considered the ultimate proof of aconcept, and Oshima et al. have demonstrated that reduc-tion of COX-2 through deletion of the COX-2 alleles in mice containing mutated APC decreases intestinal tumour bur-den. There are a few points to consider when evaluating this paper. The first point is that these investigators did not meas-ure prostaglandin levels in the resulting mice. It has been re-ported in the COX-1 and COX-2 knock-out mice that the remaining enzymatic isoform can compensate and thereby partially correct the resulting decrease in prostaglandins. This leads one to wonder whether they would have seen a larger effect on tumour number if they had deleted both the COX-1 and COX-2 genes. Another point to consider is that the background of both the COX-2 nullizygous mice and the mutant APC mice were not reported. As discussed in [53], the background of the mice can have a significant effect on tu-mour burden.
   Google Scholar
• CORMIER RT, HONG KH, HALBERG RB et al.: Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nature Genetics (1997) 17:88–91.
   PubMed Web of Science ®Google Scholar
• ••This is a final paper in a series of papers that have come fromthe Dove laboratory. It characterises the effects of genetic background on tumour number. They have elegantly iso-lated the genes that are thought to contribute to tumourigen-icity in the Min mice. Interestingly, the protein product, phospholipase, is a key enzyme in the prostaglandin biosyn-thetic pathway.
   Google Scholar
• MACPHEE M, CHEPENIK K, LIDDELL R et al.: The secre-tory phospholipase A2 gene is a candidate for the Mom/ locus, a major modifier of Apcmin-induced intes-tinal neoplasia. Cell (1995) 81:957–966.
   PubMed Web of Science ®Google Scholar
• JACOBY RF, MARSHALL DJ, NEWTON MA et al.: Chemo-prevention of spontaneous intestinal adenomas in the Apcmin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. (1996) 56:710–714.
   PubMed Web of Science ®Google Scholar
• BOOLBOL SK, DANNENBERG AJ, CHADBURN A et al.:Cyclooxygenase-2 overexpression and tumor forma-tion are blocked by sulindac in a murine model of fa-milial adenomatous polyposis. Cancer Res. (1996) 56:2556–2560.
   PubMed Web of Science ®Google Scholar
• CHIU CH, MCENTEE MF, WHELAN J: Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res. (1997) 57:4267–4273.
   PubMed Web of Science ®Google Scholar
• BEAZER-BARCLAY Y, LEVY DB, MOSER AR et al.: Sulindac suppresses tumorigenesis in the min mouse. Carcino-genesis (1996) 17:1757–1760.
   PubMed Web of Science ®Google Scholar
• BARNES CJ, LEE M: Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology (1998) 114:873–877.
   PubMed Web of Science ®Google Scholar
• MAHMOUD NN, BOOLBOL SK, DANNENBERG AJ et al: The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogen esis (1998) 19:87–91.
   PubMed Web of Science ®Google Scholar
• ••It is interesting to contrast the methods and results obtainedby Mahmoud et al. and Pizza et al. [62]. They both treat ro-dents that are predisposed to intestinal tumourigenesis with sulindac (or sulindac sulfide) or the inactive metabolite sulindac sulfone; however, the results and subsequent con-clusions are diametrically opposed.
   Google Scholar
• RAO CV, RIVENSON A, SIMI B etal.: Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. (1995) 55:1464–1472.
   Google Scholar
• PIAZZA GA, ALBERTS DS, HIXSON LJ et al.: Sulindac sul-fone inhibits azoxymethane-induced colon carcino-genesis in rats without reducing prostaglandin levels. Cancer Res. (1997) 57:2909–2915.
   PubMed Web of Science ®Google Scholar
• ••See comments for [60].
   Google Scholar
• SAMAHA HS, KELLOFF GJ, STEELE V, RAO CV, REDDY BS:Modulation of apoptosis by sulindac, curcumin, phenylethy1-3-methylcaffeate, and 6-phenylhexyl iso-thiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res. (1997) 57:1301–1305.
   PubMed Web of Science ®Google Scholar
• REDDY BS, RAO CV, SEIBERT K: Evaluation of cyclooxygenase-2 inhibitor for potential chemopre-ventive properties in colon carcinogenesis. Cancer Res. (1996) 56:4566–4569.
   PubMed Web of Science ®Google Scholar
• ••This paper and the paper by Yoshimi et al. [66] determinethe effects of COX-2 selective inhibitors on tumour burden in the AOM-treated rodent. Importantly, the inhibitors that these two investigators use are structurally distinct com-pounds since one is from the acidic sulfonamide class of inhibitors and the other is a heterocycle. Importantly, both drugs result in a decrease in tumour burden. Furthermore, the effects were seen in aberrant crypt foci, which are thought to be precursor lesions for adenoma formation.
   Google Scholar
• KAWAMORI T, RAO CV, SEIBERT K, REDDY BS: Chemo-preventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcino-genesis. Cancer Res. (1998) 58:409–412.
   PubMed Web of Science ®Google Scholar
• YOSHIMI N, KAWABATA K, HARA A et al.: Inhibitory ef-fect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in co-lon carcinogenesis of F344 rats. Jpn. J. Cancer Res. (1997) 88:1044–1051.
   PubMedGoogle Scholar
• ••See comments for [64].
   Google Scholar
• WECHTER WJ, KANTOCI D, MURRAY ED et al.: R-Flurbiprofem chemoprevention and treatment of in-testinal adenomas in the APCMin/+ mouse model: im-plications for prophylaxis and treatment of colon cancer. Cancer Res. (1997) 57:4316–4324.
   PubMed Web of Science ®Google Scholar
• RIENDEAU D, CHARLESON S, CROMLISH W et al.: Com-parison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can. J. Phys. Pharmacol. (1997) 75:1088–1095.
   PubMed Web of Science ®Google Scholar
• BRIDEAU C, KARGMAN S, LIU S et al.: A human wholeblood assay for clinical evaluation of biochemical effi-cacy of cyclooxygenase inhibitors. Inflamm. Res. (1996) 45:68–74.
   PubMed Web of Science ®Google Scholar
• SHENG H, SHAO J, KIRKLAND SC et al.: Inhibition of hu-man colon cancer cell growth by selective inhibition of cyclooxygenase-2. ./. Clin. Invest. (1997) 99:2254–2259.
   Google Scholar
• ••This study compares the effects of SC-58125 on two xeno-graft models. They evaluated HCA7 cells, which express high levels of COX-2 protein, and HCT-116 cells, which lack COX-2. SC-58125 reduced tumour formation in mice im-planted with HCA7 cells but not with HCT-116 cells.
   Google Scholar
• GOLDMAN AP, WILLIAMS CS, SHENG H et al: Meloxicam inhibits the growth of colorectal cancer cells. Carcino-genesis (1998). (In Press).
   Google Scholar
• SHIFF SJ, QIAO L, TSAI LL, RIGAS B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. (1995) 96:491–503.
   PubMed Web of Science ®Google Scholar
• QIAO L, HANIF R, SPHICAS E, SHIFF SJ, RIGAS B: Effect of aspirin on induction of apoptosis in HT-29 human co-lon adenocarcinoma cells. Biochemistry (1998) 55:53–64.
   Google Scholar
• PIAZZA GA, RAHM AK, FINN TS et al.: Apoptosis primar-ily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. (1997) 57:2452–2459.
   PubMed Web of Science ®Google Scholar
• PIAZZA GA, RAHM AL, KRUTZSCH M et al.: Antineoplas-tic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. (1995) 55:3110-3116. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(1)
   Google Scholar
• GOLDBERG Y, NASSIF II, PITTAS A et al: The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor sup-pressor and cell cycle-regulatory proteins. Oncogene (1996) 12:893–901.
   PubMed Web of Science ®Google Scholar
• HIXSON LI ALBERTS DS, KRUTZSC M et al.: Antiprolifera-tive effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol. Biomarkers Prevent. (1994) 3:433–438.
   PubMed Web of Science ®Google Scholar
• HANIF R, PITTAS A, FENG Y et al.: Effects of nonsteroidalanti-inflammatory drugs on proliferation on induc-tion of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Phar-macol. (1996) 52:237–245.
   PubMed Web of Science ®Google Scholar
• QIAO L, SHIFF SJ, RIGAS B: Sulindac sulfide inhibits theproliferation of colon cancer cells: diminished expres-sion of the proliferation markers PCNA and Ki-67. Cancer Lett. (1997) 115:229–234.
   PubMed Web of Science ®Google Scholar
• TSUJI S, KAWANO S, SAWAOKA H et al.: Evidence for in-volvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostagland. LeukoL EssenL Fatty Acids (1996) 55:179–183.
   PubMed Web of Science ®Google Scholar
• CHAN TA, MORIN PJ, VOGELSTEIN B, KINZLER KW: Mechanisms underlying nonsteroidal antiinflamma-tory drug-mediated apoptosis. Proc. Natl. Acad. Sci USA (1998) 95:681–686.
   PubMed Web of Science ®Google Scholar
• TANG DG, CHEN YQ, HONN KV: Arachidonate lipoxy-genases as essential regulators of cell survival and apoptosis. Proc. Natl. Acad. Sci USA (1996) 93:5241–5246.
   PubMed Web of Science ®Google Scholar
• ReSCHOFF J, WALLINGER S, DIETMAIER W et al.: Aspirin suppresses the mutator phenotype associated with he-reditary nonpolyposis colorectal cancer by genetic se-lection. Proc. Natl. Acad. Sci. USA (1998) 95:11301–11306.
   PubMed Web of Science ®Google Scholar
• TAFFET S, PACE J, RUSSELL S: Lymphokine maintains macrophage activation for tumor cell killing by inter-fering with the negative regulatory effect of prosta-glandin E2. J. Immunol. (1981) 127:121–124.
   PubMed Web of Science ®Google Scholar
• TAFFET S, RUSSEL S: Macrophage-mediated tumor cell killing: regulation of expression of cytolytic activity by prostaglandin E. J. Immunol. (1981) 126:424–427.
   PubMed Web of Science ®Google Scholar
• YOUNG M, WHEELER E, NEWBY M: Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma. J. Natl. Cancer Inst. (1986) 76:745–750.
   PubMed Web of Science ®Google Scholar
• TSUJII M, KAWANO S, TSUJI S et al.: Cyclooxygenase regulates angiogenesis induced by colon cancer cells [published erratum appears in Cell 1998 Jul 24;94(2):following 271]. Cell (1998) 93:705–716.
   PubMed Web of Science ®Google Scholar
• CHAN CC, BOYCE S, BRIDEAU C et al.: Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman pri-mate stomach. J. Pharmacol. Exp. Ther. (1995) 274:1531–1537.
   PubMed Web of Science ®Google Scholar
• FUTAKI N, ARAI I, HAMASAKA Y et al.: Selective inhibi-tion of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J. Pharm. Pharmacol. (1993) 45:753–755.
   PubMed Web of Science ®Google Scholar
• FUTAKI N, YOSHIKAWA K, HAMASAKA Y et al: NS-398, a novel non-steroidal anti-inflammatory drug with po-tent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol. (1993) 24:105–110.
   PubMedGoogle Scholar
• PENNING TD, TALLEY JJ, BERTENSHAW SR et al.: Synthe- sis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 445-(4-methylpheny0-3-(trifluoromethyl)-1H--pyrazol-1-yllbenze nesulfonamide (SC-58635, cele-coxib). J. Med. Chem. (1997) 40:1347–1365.
   PubMed Web of Science ®Google Scholar
• •This paper exemplifies the details that are behind drug design.
   Google Scholar
• GIERSE JK, MCDONALD JJ, HAUSER SD et al.: A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. (1996) 271:15810–15814.
   PubMed Web of Science ®Google Scholar
• PEREIRA MA, BARNES LH, STEELE VE, KELLOFF GV, LU-BET RA: Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and pre-vention of colon cancer in rats. Carcinogenesis (1996) 17:373–376.
   PubMed Web of Science ®Google Scholar